AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00324428 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
Study NCT00629746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Xomed Nerve Integrity Monitor (NIM)
Description: patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen.
Study NCT04361604 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological collection (patients co infected HIV Sras-CoV-2)
Description: Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
Study NCT02568306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0165-1562
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
Study NCT02568306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
Study NCT02208843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib tablet once daily until progression
Study NCT02587052 — intervention group
Intervention type: DRUG
Intervention: Generic tacrolimus
Description: Generic tacrolimus
Study NCT02587052 — intervention group
Intervention type: DRUG
Intervention: Prograf
Description: Prograf, the original tacrolimus
Study NCT01722409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane and 0.5 μg/kg dexmedetomidine
Description: After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
Study NCT01722409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane and 1 μg/kg dexmedetomidine
Description: After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
Study NCT02980588 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SGC directed glycemic control
Description: the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
Study NCT03328637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
Study NCT02481856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet
Study NCT02481856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01593644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine + dipyridamole
Description: adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
Study NCT03331536 — intervention group
Intervention type: PROCEDURE
Intervention: Roux en Y Gastric Bypass Pre-menopausal
Description: The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
Study NCT03331536 — intervention group
Intervention type: PROCEDURE
Intervention: Roux en Y Gastric Bypass Post-menopausal
Description: The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
Study NCT03331536 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy Pre-menopausal
Description: The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
Study NCT03331536 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy Post-menopausal
Description: The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
Study NCT03954860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drainage Tube
Description: The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
Study NCT03954860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
Study NCT03954860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
Study NCT03954860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
Study NCT03954860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
Study NCT02163148 — intervention group
Intervention type: BEHAVIORAL
Intervention: Massed speech exposure session
Description: One session consisting of 4 speech exposures, each 5 minutes long.
Study NCT00831948 — intervention group
Intervention type: GENETIC
Intervention: mitochondrial DNA mutations diagnosis
Description: Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
Study NCT03760653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise and probiotic group
Description: The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
Study NCT03760653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
Study NCT03760653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
Study NCT03177226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional TENS stimulation
Description: A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
Study NCT04361604 — intervention group
Intervention type: OTHER
Intervention: Auto-questionnaires (patients co infected HIV Sras-CoV-2)
Description: 4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
Study NCT04361604 — intervention group
Intervention type: OTHER
Intervention: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)
Description: Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
Study NCT03177226 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-Functional TENS stimulation
Description: A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
Study NCT03192709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil vaginal suppositories
Description: Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
Study NCT03192709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vaginal placebo
Description: Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
Study NCT03192709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vaginal placebo
Description: Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
Study NCT03999138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
Study NCT02145104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Study NCT01536418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 milligrams once daily, orally administered for 12 weeks
Study NCT01536418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 milligrams twice daily, orally adminstered for 12 weeks
Study NCT02145104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Study NCT00197145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW873140
Description: 400 mg twice daily
Study NCT02147223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
Study NCT02147223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
Study NCT02147223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol free intervention
Description: Calorically, micro- and macronutrient matched control product free of flavanols
Study NCT03698045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-143 Ophthalmic Solution
Description: PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
Study NCT01579825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buffer
Description: 5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
Study NCT04911244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: endobronchial sampling through bronchoscopy
Study NCT01258153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant oral solution
Description: Oral administration once daily for 7 days
Study NCT01258153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Nepadutant oral solution
Description: Oral administration once daily for 7 days
Study NCT02161458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg for 2 weeks
Description: 30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
Study NCT02161458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg for 8 weeks
Description: 30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
Study NCT02161458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 30mg for 8 weeks
Description: 30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
Study NCT02161458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
Study NCT03056378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard RBCs
Description: Transfusion of standard pRBCs that are matched for C, E and K
Study NCT03056378 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard RBCs
Description: Transfusion of standard pRBCs that are matched for C, E and K
Study NCT00774878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: AVE1642 is administered intravenously at the dose of 8 mg/kg.
Study NCT00774878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
Study NCT00774878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
Study NCT04534738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
Study NCT02384382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02604693 — intervention group
Intervention type: OTHER
Intervention: Nothing
Description: No interventions will be administered.
Study NCT04805203 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample analyses
Description: maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
Study NCT02737553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enclosed morcellation
Description: After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
Study NCT02737553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal morcellation
Description: After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
Study NCT01082510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacille Calmette-Guerin
Description: The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
Study NCT01082510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uracil-tegafur
Description: The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
Study NCT02410278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
Study NCT02410278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: As described in the treatment arm
Study NCT02410278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT03076853 — intervention group
Intervention type: OTHER
Intervention: Opening of the Pharmaceutical Record
Description: After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
Study NCT00148122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
Study NCT00148122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
Study NCT00293709 — intervention group
Intervention type: DRUG
Intervention: etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.